Erasca Faces Securities Class Action Over ERAS-0015 Disclosures

Investors who sustained losses exceeding $100,000 in Erasca, Inc. securities face an August 10, 2026, deadline to file as lead plaintiffs in a pending class action lawsuit. The litigation, filed in the Southern District of California, centers on allegations that the company misled shareholders regarding its flagship ERAS-0015 program.

Today, 05:17· Money Talk· 2,558 reads

Erasca Faces Securities Class Action Over ERAS-0015 Disclosures

The lawsuit, Cheng v. Erasca, Inc., alleges that Erasca and its executives violated federal securities laws by failing to disclose material risks during the period between January 14, 2025, and April 26, 2026. Plaintiffs claim the company’s positive public statements regarding its pan-RAS molecular glue candidate, ERAS-0015, lacked a reasonable basis.

Central to the complaint are assertions that preclinical data for the drug relied on improper comparisons to Revolution Medicines, Inc. These comparisons allegedly exposed Erasca to significant risks concerning potential violations of patent and trade secret protections. Investors seeking to discuss their legal options or participate in the proceedings can contact Kahn Swick & Foti, LLC, or utilize the ClaimsFiler information service to manage their claims process.

Erasca Faces Securities Class Action Over ERAS-0015 Disclosures

Comments (0)